ArticleFrontiers in microbiology2019
Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria.
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus onFrontiers in microbiology · 2025Pooled it
- Towards Antimicrobial Formulations of Repurposed Drugs and Cationic Surfactants: Efficacy, Cytotoxicity on Human Cell Lines, and Ecotoxicity in Aquatic Models.Antibiotics (Basel, Switzerland) · 2026Article
- Advances in Ciprofloxacin Derivatives: Emerging Strategies to Combat Antimicrobial Resistance.Topics in current chemistry (Cham) · 2026Review
- Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli.The Journal of antibiotics · 2026Article
- Combination of mitomycin C and low-dose metronidazole synergistically againstAntimicrobial agents and chemotherapy · 2025Article
- Combination therapy delays antimicrobial resistance after adaptive laboratory evolution ofAntimicrobial agents and chemotherapy · 2025Article
- Development of polymyxin- and aminoglycoside-based outer membrane permeabilizers: a review.Frontiers in microbiology · 2025Review
- Repurposing the Anticancer Drug Cisplatin for Antibacterial Therapy: Evaluating Its Efficacy AgainstInfection and drug resistance · 2025Article
- Preliminary insights into the potential role of Acanthamoeba-Pseudomonas interactions in the development of antibiotic resistance.Access microbiology · 2025Article
- Busulfan inhibitsFrontiers in cellular and infection microbiology · 2025Article
- 5-Fluorouracil Inhibits Bacterial Growth and Reduces Biofilm in Addition to Having Synergetic Effects with Gentamicin AgainstMicroorganisms · 2024Article
- Mitomycin C as an Anti-Persister Strategy againstAntibiotics (Basel, Switzerland) · 2024Article
- The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug.Antibiotics (Basel, Switzerland) · 2024Review
- Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models ofAntibiotics (Basel, Switzerland) · 2024Article
- Repurposing Mitomycin C in Combination with Pentamidine or Gentamicin to Treat Infections with Multi-Drug-Resistant (MDR)Antibiotics (Basel, Switzerland) · 2024Article
- Multidrug Resistant Enteric Bacteria from Cancer Patients Admitted in Douala Laquintinie Hospital, Littoral Region of Cameroon.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study.Journal of cancer research and clinical oncology · 2023Article
- Antibody-Drug Conjugates to Treat Bacterial Biofilms via Targeting and Extracellular Drug Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer.International journal of molecular sciences · 2022Article
- Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae.Antimicrobial agents and chemotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of therapeutic options to treat infections caused by multidrug-resistant (MDR) pathogens, especially Gram-negative bacteria, is apparent. Therefore, it is imperative to develop new strategies to address the problem of antimicrobial resistance. Repurposing non-antibiotic commercial drugs for antimicrobial therapy presents a viable option. We screened six anticancer drugs for their potential use in antimicrobial therapy. Here, we provide
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.